-
Product Insights
NewNet Present Value Model: Ventyx Biosciences Inc’s VTX-958
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Ventyx Biosciences Inc’s VTX-002
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
Innovation and Patenting activity of Ventyx Biosciences Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ventyx Biosciences Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Triple-Negative Breast Cancer (TNBC) Drug Details: Margetuximab (Margenza)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Metastatic Melanoma Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Product Insights
Cryopyrin-Associated Periodic Syndromes – Drugs In Development, 2023
Global Markets Direct’s, ‘Cryopyrin-Associated Periodic Syndromes - Drugs In Development, 2023’, provides an overview of the Cryopyrin-Associated Periodic Syndromes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cryopyrin-Associated Periodic Syndromes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Eosinophilic Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Eosinophilic Esophagitis - Drugs In Development, 2023’, provides an overview of the Eosinophilic Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Esophageal Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Diseases - Drugs In Development, 2023’, provides an overview of the Esophageal Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Esophagitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophagitis - Drugs In Development, 2023’, provides an overview of the Esophagitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...